Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Observational study of haloperidol in hospitalized patients with COVID-19

Abstract : Background: Haloperidol, a widely used antipsychotic, has been suggested as potentially useful for patients with COVID-19 on the grounds of its in-vitro antiviral effects against SARS-CoV-2, possibly through sigma-1 receptor antagonist effect. Methods: We examined the associations of haloperidol use with intubation or death and time to discharge home among adult patients hospitalized for COVID-19 at Assistance Publique-Hôpitaux de Paris (AP-HP) Greater Paris University hospitals. Study baseline was defined as the date of hospital admission. The primary endpoint was a composite of intubation or death and the secondary endpoint was discharge home among survivors in time-to-event analyses. In the primary analyses, we compared these two outcomes between patients receiving and not receiving haloperidol using univariate Cox regression models in matched analytic samples based on patient characteristics and other psychotropic medications. Sensitivity analyses included propensity score analyses with inverse probability weighting and multivariable Cox regression models. Results: Of 15,121 adult inpatients with a positive COVID-19 PT-PCR test, 39 patients (0.03%) received haloperidol within the first 48 hours of admission. Over a mean follow-up of 13.8 days (SD = 17.9), 2,024 patients (13.4%) had a primary end-point event and 10,179 patients (77.6%) were discharged home at the time of study end on May 1st. The primary endpoint occurred in 9 patients (23.1%) who received haloperidol and 2,015 patients (13.4%) who did not. The secondary endpoint of discharge home occurred in 16 patients (61.5%) who received haloperidol and 9,907 patients (85.8%) who did not. There were no significant associations between haloperidol use and the primary (HR, 0.80; 95% CI, 0.39 to 1.62, p = 0.531) and secondary (HR, 1.30; 95% CI, 0.74 to 2.28, p = 0.355) endpoints. Results were similar in multiple sensitivity analyses. Conclusion: Findings from this multicenter observational study suggest that haloperidol use prescribed at a mean dose of 4.5 mg per day (SD = 5.2) for a mean duration of 8.4 days (SD = 7.2) may not be associated with risk of intubation or death, or with time to discharge home, among adult patients hospitalized for COVID-19.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal.sorbonne-universite.fr/hal-03148564
Contributeur : Hal Sorbonne Université Gestionnaire Connectez-vous pour contacter le contributeur
Soumis le : lundi 22 février 2021 - 12:41:06
Dernière modification le : jeudi 2 septembre 2021 - 09:08:50
Archivage à long terme le : : dimanche 23 mai 2021 - 18:36:32

Fichier

journal.pone.0247122.pdf
Publication financée par une institution

Identifiants

Citation

Nicolas Hoertel, Marina Sánchez-Rico, Raphaël Vernet, Anne-Sophie Jannot, Antoine Neuraz, et al.. Observational study of haloperidol in hospitalized patients with COVID-19. PLoS ONE, Public Library of Science, 2021, 16 (2), pp.e0247122. ⟨10.1371/journal.pone.0247122⟩. ⟨hal-03148564⟩

Partager

Métriques

Consultations de la notice

302

Téléchargements de fichiers

250